In the Han:SPRD Cy rat model, L-arginine (a substrate for NOS via the well-established L-arginine-NOS pathway [12]) increased NO metabolites, but the therapeutic efficacy on cystic kidney disease was mild [13], possibly due to first-pass metabolism [14]. Here, NOS2 is linked to cystic kidney disease.